Researchers have identified a new treatment approach for acute HIV-infected patients, which targets human proteins rather than the virus.
Researchers have reported that 86% of heterosexuals at high-risk for HIV would use a home-based testing kit sent by post, and almost all of these individuals would seek medical advice following a positive result.
A child born with HIV has been found to suppress the infection without the reliance on conventional antiretroviral therapy; this may have future implications on the therapeutic approaches to HIV especially in infants.
A vaginal ring, hoped to prevent HIV, has been reported to be safe and acceptable in a US study examining use in teenage girls, a particular risk group for this virus.
Results from the early-stage APPROACH trial have demonstrated an investigational HIV vaccine regimen, based on mosaic vaccines, has been well-tolerated and immunogenic in healthy participants.
Interval dosing with Vorinostat could reverse HIV latency, however, additional measures are still required to achieve complete HIV reservoir depletion, study suggests.
A new assay has been developed for the faster, cheaper and less labour-intensive detection of replicating latent HIV in infected individuals.
A team from the Scripps Research Institute have determined the structure of clade C HIV-1 envelope glycoprotein, an immunogen that could be utilized in a future HIV vaccine.
Researchers have utilized mathematical modelling to assess whether US goals for HIV transmission and incidence are possible, discovering a serious reduction is achievable if other key goals are met.
CRISPR/Cas9 has been demonstrated to excise HIV-1 DNA from host tissues in vivo according to new research; this marks a major step towards a permanent cure for HIV infection.